X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Wall Street Cautiously Optimistic After Gene Therapy Deals

    RoboCap: A Robotic Capsule to Improve Gut Drug Delivery

    Once More, M&As In Biotechechnology Industry Are Thriving

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

AdaptVac teams up with AGC Biologics to develop and produce COVID-19 vaccine

Content Team by Content Team
27th April 2020
in Drug Development, Press Statements, Research & Development
AdaptVac teams up with AGC Biologics to develop and produce COVID-19 vaccine

AGC Biologics , a leading provider of biopharmaceutical contract development and manufacturing organization (CDMO), announced its partnership with AdaptVac. The partnership was formed to jointly develop and manufacture a COVID-19 vaccine. AdaptVac is developing a SARS-CoV-2 vaccine together with its PREVENT-nCoV consortium partners funded by the EU initiative Horizon 2020. The COVID-19 pandemic is constantly evolving, and AdaptVac’s Virus-Like-Particle (VLP) technology could offer a solution to protect against new SARS-CoV-2 infections.

AdaptVac’s technology enables the accelerated development of a COVID-19 vaccine, and subsequently a possible early start of related clinical trials in late 2020. Virus-Like Particles (VLPs) represent a significant advance in the development of subunits Vaccines, since this technology can combine high safety with good effectiveness. The particulate nature and the dense structure of the subunits make them an ideal framework for vaccine antigens.

“We firmly believe that our capsid-based virus-like-particle-display technology will be a key player in global emergencies such as the COVID-19 epidemic, and have targeted AGC Biologics as our trusted development partner and production of this vaccine. We are grateful to AGC for contributing to COVID-19 vaccine development, as this additional support will allow us to tackle vaccine production in a shorter timeframe, “said Wian de Jongh, CEO of AdaptVac .

“The urgency to design and manufacture a vaccine against COVID-19 couldn’t be greater,” said Patricio Massera , CEO of AGC Biologics. “We are honored to be working with AdaptVac and to be part of the consortium that does so developing an efficient vaccine. We value partnership-based cooperation and are convinced that the only way we can fight the pandemic is through cooperation. ”

About AdaptVac:
AdaptVac is committed to accelerating the development of safe and effective therapeutic and prophylactic vaccines as treatment and prophylaxis for specific cancers, infectious diseases and immunological disorders. AdaptVac ApS is a joint venture between ExpreS2ion Biotechnologies ApS, a wholly-owned subsidiary of ExpreS2ion Biotech Holding AB, listed on NASDAQ First North, and the spin-out company NextGen Vaccines ApS of the University of Copenhagen. The aim of the joint venture is to establish itself as a top-class organization for the development of competitive vaccines and therapeutic agents against infectious diseases, cancer and immunological disorders. The combination of ExpreS2 technology for protein expression in insect cells with the unique know-how in the field of virus-like-particle (VLP) technology from NextGen makes AdaptVac a strong and versatile player in the field of new vaccines and immunotherapies.

About AGC Biologics:
AGC Biologics is a leading global contract development and manufacturing organization (CDMO) that aims to provide the highest level of service to customers and partners. The company currently employs more than 900 people worldwide. AGC Biologics’ global network spans three continents with cGMP compliant facilities in Seattle, Washington ; Copenhagen, Denmark; Heidelberg, Germany; and Chiba, Japan .

AGC Biologics offers in-depth industry knowledge and unique, customer-specific services for the scale-up and cGMP production of protein-based therapeutics, from preclinical to commercial production for mammalian and microbial cells. The integrated range of services includes plasmids (GMP pDNA), the development of cell lines and bioprocesses, formulations, analytical tests, the development and conjugation of antibody drugs, cell banking and storage as well as protein expression – including the patented CHEF1® expression system for production in mammalian cells.

Previous Post

CENTOGENE Releases a New Swab Product to Facilitate the Simple Diagnosis of COVID-19

Next Post

ProteoGenix to accelerate the discovery of SARS-CoV-2 antibodies with first human immune COVID-19 library

Related Posts

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Clinical Trials

Cancer Clinical Trials Get A Brand New Platform In Melbourne

3rd November 2022
News

Report Indicates UK £62bn Behind In Global R&D Investment

3rd November 2022
Next Post
ProteoGenix to accelerate the discovery of SARS-CoV-2 antibodies with first human immune COVID-19 library

ProteoGenix to accelerate the discovery of SARS-CoV-2 antibodies with first human immune COVID-19 library

Latest News

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Facilities & Operation

CPhI Pharma Index Shows Unprecedented Global Pharma Optimism

5th November 2022
$2 Million Gene Therapy Might Become The Standard In The US
Drug Development

$2 Million Gene Therapy Might Become The Standard In The US

5th November 2022
News

Cancer Medicine Prices Jump 53% In Five Years In The U.S

3rd November 2022
FDA Approvals

Food And Drug Administration User Fee Has Been Reauthorized

3rd November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In